drugset / Trial / NCT04250506

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

NCT04250506

Phase 1 Completed 36 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverQuadruple-blindOther

Summary

A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects

Timeline

Start
2020-02-28
Primary completion
2020-07-22
Completion
2020-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral
Subject Daridorexant Small molecule 200 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.